Pidilite Industries Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/p2acr26gpc9l2xa7ynusa5cm.pdf

Key Takeaways


Volume Growth & Demand

Vats: “If the country's growth is in the 6.5, 7 range in real terms, our UVG growth should remain double digit and we would like to keep inching it up that because a lot of these things we do, we create a lot of demand ourselves.”

Margin Walk & Input-Cost Dynamics

Vats: “We are very clear, as a company and as leaders that we will not transmit this through and through to the market. You cannot say my price in 1 month is like this, second month is like this, third month is like that. We will manage it for the year. We will manage demand as well.”
Batra: “...if you have to be at 50% gross margin, you have to price in 2x of the cost increase to be at the same percentage level of margin. And that's not something that can be done overnight, right?”

Construction Chemicals: Retail & Projects

Vats: “It's a bit like the duck. There's a lot of paddling happening under the water. You don't see it, it seems calm, but we'll move faster.”

Core Brands & Innovation Pipeline


Competitive Position & Pricing Philosophy

Vats: “...trying to go really high on margin at times could compromise the growth opportunity in a country like India, could also open up the segments for competitors and make it attractive for wrong reasons.”
Batra: “...we are not chasing volume for volume's sake. For us, the mantra is profitable underlying volume growth.”

AI & Productivity Initiatives


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin corridor20–24%, ideally at the slightly higher endH2 FY27
Price increaseOne round taken Oct 1 on Fevicol and Dr. Fixit; another possibleLate Q3 or early Q4 FY27
UVGDouble-digitNear term (no end date)
UVG aspirationMove from double-digit to early teensMedium term (no date)
Fevicol Multi Lock and X-PerNational launchNovember 2026
Roff and Dr. Fixit campaignsSignificantly higher visibilityQ3 FY27
Projects reorganization benefitsFurther benefits expectedQ3 FY27
AI manpower reductionDeferred to Phase 2 discussionNo timeline given
VAM backward integrationNo plans to set up a plantOngoing stance

Key Metrics

MetricQ2 FY27
Stand-alone revenueUnder ₹4,000 cr, 21.7% nominal growth
Underlying volume growth (UVG)10.7%, broad-based
Consumer & Bazaar UVG11.1%
B2B UVG9.2%
Stand-alone EBITDA margin20.4%, declined 430 bps YoY; at lower end of 20–24% corridor
Gross margin decline720 bps YoY, driven by elevated input costs
VAM consumption rate$1,630, nearly double YoY; vs $1,370 in Q1 FY27
H1 FY27 stand-alone revenue growth22%
H1 FY27 UVG11%
H1 FY27 EBITDA margin23.5%, very much towards the upper end of 20–24% corridor
International subsidiaries revenue growth21.8%
International subsidiaries EBITDA growth53%
Domestic subsidiaries revenue growth22.2%
Price increase taken October 13–5% on Fevicol and Dr. Fixit in areas of heightened inflation; follows 12–15% staggered increase in Q1, with more price increases to come in October
Current VAM priceAround $1,200